RenovoRx (RNXT) Gross Profit (2025 - 2026)
RenovoRx (RNXT) posted Gross Profit of $479000.0 for Q1 2026, up 128.1% sequentially from $210000.0 in Q4 2025, and up 365.05% YoY from $103000.0 in Q1 2025.
RenovoRx (RNXT) Gross Profit (2025 - 2026) Analysis & Trends
RenovoRx has reported Gross Profit for 2 years, with the latest figure at $479000.0 in Q1 2026.
- Quarterly Gross Profit rose 365.05% year-over-year to $479000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $1.2 million (changed N/A YoY) and the FY2025 annual result came in at $796000.0, up 1751.16% from the prior year.
- Gross Profit climbed to $479000.0 in Q1 2026 per RNXT's latest filing, from $210000.0 in the prior quarter.
- Over five years, Gross Profit peaked at $479000.0 in Q1 2026 and troughed at $103000.0 in Q1 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn |
| 10 | RenovoRx | 61.96 Mn | 61.96 Mn | 766,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 766,000.00 |
| Jun 30, 2026 | 766,000.00 |
| Mar 31, 2026 | 479,000.00 |
| Mar 31, 2026 | 479,000.00 |
| Dec 31, 2025 | 210,000.00 |
| Dec 31, 2025 | 210,000.00 |
| Sep 30, 2025 | 213,000.00 |
| Sep 30, 2025 | 213,000.00 |
| Jun 30, 2025 | 270,000.00 |
| Jun 30, 2025 | 270,000.00 |
| Mar 31, 2025 | 103,000.00 |
| Mar 31, 2025 | 103,000.00 |